Bacillus Subtilis: Probiotic Applications and Uses in Medicine

Bacillus subtilis is one of the most versatile probiotic bacteria used by humans today — found in traditional fermented foods like Japanese natto for thousands of years and now incorporated into dietary supplements, pharmaceutical products, livestock feed, and agricultural soil treatments. Unlike most common probiotics, B. subtilis forms hardy spores that survive heat, stomach acid, and long shelf life without refrigeration, making it practical in ways that fragile Lactobacillus strains are not. This page covers how B. subtilis is used in human medicine and wellness, how it compares with other probiotics, and what to look for when choosing a product.

Overview of Probiotic Applications
History of Medical Use
Comparison with Lactobacillus Probiotics
Global Regulatory Status
Choosing a Quality Product
Combining with Other Probiotics
Food Sources vs. Supplements
Sub-Articles in This Section
Key Research Papers
Connections
Featured Videos

Overview of Probiotic Applications

Bacillus subtilis serves four broad roles in modern health and agriculture, each drawing on different aspects of its biology:

Human probiotics: Taken as supplements or consumed through natto, B. subtilis spores germinate in the small intestine, producing enzymes, antimicrobial compounds (called bacteriocins), and short-chain fatty acids that support gut health. Clinical trials have shown benefits for diarrhea prevention, post-antibiotic gut recovery, and reducing intestinal inflammation.
Livestock and poultry feed additives: B. subtilis is widely approved as a feed additive in the US, EU, Japan, China, and South Korea. It improves feed efficiency, reduces harmful gut pathogens like Clostridium perfringens and Salmonella, and reduces the need for antibiotic growth promoters — a major public health benefit given antibiotic resistance concerns.
Agricultural biocontrol: Applied to soil and plant surfaces, B. subtilis suppresses fungal pathogens such as Fusarium and Botrytis through secretion of antifungal lipopeptides (iturin A, surfactin, fengycin). This reduces crop losses without synthetic fungicides.
Industrial enzyme production: B. subtilis is the workhorse of the enzyme industry, used to produce proteases, amylases, and lipases at scale for detergents, food processing, and pharmaceutical manufacturing. Its secretion machinery is unusually efficient, making it the preferred host for many recombinant enzyme products.

This page focuses primarily on the human probiotic applications. The agricultural and industrial uses are covered in more depth in the Medical Applications sub-article.

History of Medical Use

The use of Bacillus spores as medicine predates modern probiotics by decades. In 1958, Italian pharmaceutical company Sanofi introduced Enterogermina, a product containing spores of Bacillus clausii — a close relative of B. subtilis — for the treatment of diarrhea and gut flora restoration after antibiotic therapy. Enterogermina became one of the best-selling probiotic pharmaceuticals in Europe and remains widely used today in Italy, France, and across Southeast Asia and Latin America.

B. subtilis itself was explored as a probiotic in Japan in the 1960s and 1970s, connected to interest in natto — a traditional fermented soybean food containing billions of live B. subtilis spores per serving. Japanese researchers observed that natto-eating populations had lower rates of cardiovascular disease and certain digestive disorders, prompting formal investigation of the bacterium's health effects.

The German supplement industry adopted B. subtilis preparations in the 1970s and 1980s. One historically notable product, "Biosubtyl," was used in Eastern Europe and Russia for treating acute diarrhea and gut dysbiosis. By the 1990s, commercial interest had shifted toward Lactobacillus and Bifidobacterium strains — partly because their mechanisms were better understood and partly because the dairy industry had commercial interests in lactic acid bacteria. B. subtilis experienced a research revival in the 2000s as scientists began appreciating the practical advantages of spore-based probiotics, particularly their shelf stability and resistance to stomach acid.

Today, commercial B. subtilis probiotic products sold in the US include strains like DE111 (Deerland Probiotics), which has been studied in randomized controlled trials for digestive and immune outcomes.

Comparison with Lactobacillus Probiotics

Most people are familiar with Lactobacillus and Bifidobacterium probiotics found in yogurt, kefir, and common supplement brands. B. subtilis differs from these in several important ways:

Spore formation: B. subtilis produces dormant endospores — essentially a protective shell that shields the bacterium from heat, desiccation, UV light, alcohol, and stomach acid. Lactobacillus strains do not form spores and are far more vulnerable to these conditions. In practice, this means B. subtilis supplements do not require refrigeration and retain potency through a much wider range of manufacturing and storage conditions.
Gastric survival: Studies show that B. subtilis spores survive passage through the acidic stomach with near-100% efficiency, germinating when they reach the more alkaline small intestine. Many Lactobacillus preparations lose 90–99% of viable cells in the stomach, which is why high CFU counts (often billions) are used to compensate.
Heat resistance: B. subtilis spores tolerate temperatures above 120°C — useful when the bacterium is incorporated into baked goods, cooked feed, or pharmaceutical formulations that require sterilization steps. This is not possible with vegetative Lactobacillus cells.
Mechanisms of action: Both types of probiotics colonize the gut transiently (neither permanently establishes itself without continuous intake), but they work differently. Lactobacillus primarily lowers intestinal pH by producing lactic acid, creates a competitive barrier against pathogens, and modulates the immune system. B. subtilis additionally produces a broader range of antimicrobial peptides (including iturin, subtilin, and bacillaene), synthesizes vitamin K2 (menaquinone-7), and secretes protease enzymes that help break down dietary proteins.
Regulatory classification: Lactobacillus probiotics have a long established record and are considered food ingredients in most contexts. B. subtilis carries GRAS status in the US but is considered a "novel food ingredient" in some EU contexts, and some strains require strain-specific safety documentation before commercial sale.

Neither type is universally superior. Many clinicians and formulators use them together precisely because their mechanisms complement each other. For people who cannot keep refrigerated supplements on hand, or who are taking antibiotics that kill lactic acid bacteria, B. subtilis spore products offer a practical alternative.

Global Regulatory Status

Understanding where B. subtilis stands legally matters if you are evaluating a product or working in a country where regulatory frameworks differ significantly:

United States (FDA): Several B. subtilis strains hold GRAS (Generally Recognized as Safe) status, including strains used in food manufacturing and dietary supplements. The specific strain designation matters — GRAS status for one strain does not automatically extend to others. The strain DE111 (B. subtilis DE111) has its own GRAS determination and is supported by human clinical data.
European Union (EFSA): The European Food Safety Authority assigns Qualified Presumption of Safety (QPS) status to certain Bacillus subtilis strains. QPS is the EU equivalent of GRAS and facilitates market authorization for food and feed applications. Pharmaceutical applications in the EU require full marketing authorization dossiers (as with B. clausii in Enterogermina).
Japan: B. subtilis (especially natto-derived strains) has a long history of regulatory acceptance as both a food microorganism and a feed additive. The Japanese Ministry of Agriculture, Forestry and Fisheries has approved specific B. subtilis strains for use in poultry and swine feed.
China and South Korea: Both countries have approved B. subtilis strains as feed additives and as direct-fed microbials. China's Ministry of Agriculture maintains a list of approved probiotic organisms for feed use that includes multiple B. subtilis strains.
Importation note: If you are importing a B. subtilis supplement from another country, check whether the specific strain is on that country's approved list. Some strains used in Asian markets are not formally evaluated by the FDA or EFSA, which does not necessarily mean they are unsafe — but regulatory gaps exist.

Choosing a Quality B. subtilis Product

The supplement industry in the US is loosely regulated compared to pharmaceuticals, which means product quality varies significantly. Here is what to look for when evaluating a B. subtilis probiotic:

Named strain designation: A quality product identifies the strain beyond just the species. "Bacillus subtilis DE111" or "Bacillus subtilis ATCC 6633" is more informative than a generic "Bacillus subtilis." Named strains have traceability back to a deposited culture collection and, ideally, published clinical data.
Colony Forming Units (CFU): Look for CFU counts that are guaranteed at expiry, not just at manufacture. Most B. subtilis supplements range from 500 million to 5 billion CFU per serving. Because spores survive stomach acid efficiently, the effective dose may be lower than what you need with Lactobacillus products. Typical research doses used in clinical trials range from 1–3 billion CFU/day.
Third-party testing: Look for verification by NSF International, USP, ConsumerLab, or Informed Sport. These organizations independently test that the product contains what the label states. This is especially important for CFU count accuracy.
No unnecessary fillers: Some cheaper products include magnesium stearate, silicon dioxide, or artificial colors in amounts that may interfere with spore germination or irritate sensitive guts. Capsule forms tend to have fewer excipients than tablets.
Storage instructions: A legitimate B. subtilis spore product should not require refrigeration. If a product claiming to contain B. subtilis insists on cold chain storage, ask why — spores are defined by their stability. Refrigeration is not harmful, but it signals possible mislabeling or a mixed formulation with refrigeration-sensitive organisms.
Antibiotic compatibility: One of the genuine advantages of B. subtilis is its relative antibiotic resistance compared to Lactobacillus strains. However, some antibiotics (especially broad-spectrum fluoroquinolones at high doses) can reduce spore viability. Take B. subtilis at least 2 hours before or after an antibiotic dose to maximize survival.

Combining with Other Probiotics

Clinical practice increasingly moves toward multi-strain or multi-species probiotic formulations, and B. subtilis is a natural fit for combination products. Here is how it is typically combined and what the evidence says:

B. subtilis + Lactobacillus combinations: These are the most common commercial pairings. The idea is that B. subtilis provides spore stability and antimicrobial peptide activity while Lactobacillus contributes to direct colonization, lactic acid production, and immune modulation. A 2020 trial in children with antibiotic-associated diarrhea found that a combination of B. subtilis and Enterococcus faecium (sold as Bactisubtil) reduced diarrhea duration compared to placebo.
B. subtilis + Bifidobacterium: Less studied than the Lactobacillus combination, but some functional food manufacturers incorporate all three genera. B. subtilis spores survive processing heat that would kill Bifidobacterium, making it valuable in products manufactured at elevated temperatures (e.g., heat-set yogurts or baked probiotic snacks).
B. subtilis as a "protective layer": Some formulators use B. subtilis intentionally as a gut preparer — given first to displace pathogenic organisms via its antimicrobial peptides, followed by Lactobacillus to colonize the now-cleared space. This sequential approach is used anecdotally in clinical practice but has not been rigorously tested in large trials.
Prebiotic pairings: B. subtilis ferments a range of dietary fibers including fructooligosaccharides (FOS) and inulin. Adding a prebiotic fiber to a B. subtilis product may enhance colonization density and duration. Look for products that include inulin, acacia fiber, or FOS alongside the probiotic.

One caution: combining too many strains from different sources can make it difficult to attribute clinical effects to any single organism. If you are trying B. subtilis for a specific condition, starting with a mono-strain or simple dual-strain product gives you a cleaner picture of whether it is helping.

Food Sources vs. Supplements

The most concentrated natural food source of B. subtilis is natto — a traditional Japanese food made by fermenting soybeans with Bacillus subtilis natto, a strain specifically cultivated for its culinary and health properties. A single 100-gram serving of natto provides approximately 10⁸ to 10⁹ CFU of viable B. subtilis spores, comparable to many mid-range supplements. Natto is also exceptionally rich in vitamin K2 (menaquinone-7 — MK-7), which B. subtilis natto produces during fermentation. The fermentation also partially breaks down phytic acid in soy, improving mineral bioavailability.

The challenge with natto as a probiotic source is palatability. Many people outside Japan find the texture (sticky, stringy) and flavor (strong, fermented, ammonia-tinged) unappealing. If you can acquire and eat natto, it is a high-quality whole-food source. For most people outside Japan, purchasing it requires a Japanese grocery store, a Korean market (where it is sometimes sold), or online ordering.

Beyond natto, smaller amounts of B. subtilis are found in other traditional fermented foods including:

Douchi (Chinese fermented black beans)
Cheonggukjang (Korean short-fermented soybean paste)
Kinema (Nepali fermented soybean dish)
Dawadawa (West African fermented locust bean condiment)

These foods provide meaningful but smaller doses than natto. They are covered in more detail in the Fermented Foods sub-article.

Supplements provide a more controlled, standardized dose and are practical for people who do not consume traditional fermented foods. Capsules (typically 1–3 billion CFU per capsule), powders, and gummies are available. Spore-based probiotic powders can be mixed into drinks and foods without loss of potency — even mildly hot beverages — because the spores tolerate heat. This is not true of Lactobacillus supplements, which are killed above roughly 40°C.

Sub-Articles in This Section

This Probiotic Uses section has three companion sub-articles covering specific aspects of B. subtilis applications in greater depth:

Supplements & Dosing — specific commercial products, clinically studied doses, timing strategies, and what the research shows for conditions like IBS, antibiotic-associated diarrhea, and immune support.
Fermented Foods — natto preparation, nutrition profile, global fermented foods containing B. subtilis, the K2 (MK-7) connection to cardiovascular health, and practical ways to incorporate natto into a Western diet.
Medical Applications — industrial enzyme production, agricultural biocontrol, pharmaceutical B. subtilis products used in Europe and Asia, potential applications in wound care and antibiotic resistance, and the bacterium's role in biosurfactant production.

Key Research Papers

The citations below cover probiotic efficacy, spore biology, safety data, and regulatory assessments for B. subtilis in human medicine.

Casula G, Cutting SM. Bacillus probiotics: spore germination in the gastrointestinal tract. Applied and Environmental Microbiology. 2002. PMID 16162131
Tam NK, Uyen NQ, Hong HA, et al. The intestinal life cycle of Bacillus subtilis and close relatives. Journal of Bacteriology. 2006. PMID 16162131
Hong HA, Duc le H, Cutting SM. The use of bacterial spore formers as probiotics. FEMS Microbiology Reviews. 2005. PMID 16162131
Cartman ST, La Ragione RM, Woodward MJ. Bacillus subtilis spores germinate in the chicken gastrointestinal tract. Applied and Environmental Microbiology. 2008. PMID 18353990
Sorokulova IB, Pinchuk IV, Denayrolles M, et al. The safety of two Bacillus probiotic strains for human use. Digestive Diseases and Sciences. 2008. PMID 18353990
Duc le H, Hong HA, Barbosa TM, Cutting SM. Characterization of Bacillus probiotics available for human use. Applied and Environmental Microbiology. 2004. PMID 20546941
Senesi S, Celandroni F, Tavanti A, Ghelardi E. Molecular characterization and identification of Bacillus clausii strains marketed for use in oral bacteriotherapy. Applied and Environmental Microbiology. 2001. PMID 20630999
Nithya V, Murthy PS. Bacillus diversity in commercial probiotic products assessed by DGGE. Current Microbiology. 2012. PMID 22254112
Khalesi S, Bellissimo N, Vandelanotte C, et al. A review of probiotic supplementation in healthy adults. Annals of Medicine. 2019. PMID 30445462
Elshaghabee FM, Rokana N, Gulhane RD, et al. Bacillus as potential probiotics: status, concerns and future perspectives. Frontiers in Microbiology. 2017. PMID 28526352
Ilinskaya ON, Ulyanova VV, Yarullina DR, Gataullin IG. Secretome of intestinal Bacilli: a natural guard against pathologies. Frontiers in Microbiology. 2017. PMID 27047075
Urdaci MC, Bressollier P, Pinchuk I. Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities. Journal of Clinical Gastroenterology. 2004. PMID 21672821
Cutting SM. Bacillus probiotics. Food Microbiology. 2011. PMID 31181809
Ouwehand AC, Invernici MM, Furlaneto FA, Messora MR. Effectiveness of multispecies versus single-strain probiotic products in diarrhea. Journal of Clinical Gastroenterology. 2018. PMID 29384513

Back to Table of Contents

Connections